MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, URGN had -$2,600K decrease in cash & cash equivalents over the period. -$42,357K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,600K
Free Cash flow
-$42,357K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-33,347 -93,783
Depreciation and amortization
80 152
Accrued financing on prepaid forward obligation
1,472 123
Accretion on marketable securities
160 1,640
Share-based compensation
3,027 5,802
Amortization (accretion) of discount on long-term debt
-397 774
Amortization of right of use assets
559 941
Acquisitions of ipr&d
0 3,128
Inventory
1,213 -2,099
Accounts receivable, net
54 -653
Prepaid expenses and other current assets
67 3,210
Other non-current assets
5,958 212
Accounts payable and accrued expenses
-4,789 3,531
Employee related accrued expenses
-532 1,076
Other current liabilities
-263 62
Lease liabilities
-628 -1,344
Restricted deposit
0 -1
Net cash used in operating activities
-42,270 -81,849
Purchases of marketable securities
8,721 68,140
Maturities of marketable securities
40,206 70,768
Purchases of property and equipment
87 185
Net cash provided by investing activities
31,398 2,443
Proceeds from exercise of options into ordinary shares
302 327
Proceeds from issuance of long-term debt
0 -
Proceeds from pre-funded warrant issuance, net of issuance costs
0 3
Proceeds from ordinary shares issuances, net of issuance costs
7,970 0
Net cash provided by financing activities
8,272 330
Increase (decrease) in cash and cash equivalents
-2,600 -79,076
Cash and cash equivalents at beginning of period
173,062 -
Cash and cash equivalents at end of period
91,386 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN)